Why are studies investigating combinations of azacitidine and ruxolitinib in AML?
Research is underway to explore potential synergies between azacitidine and ruxolitinib in treating Acute Myeloid Leukemia (AML) [1]. Azacitidine is a DNA methyltransferase inhibitor used in treating myelodysplastic syndromes (MDS) and certain types of AML. It has shown promise in treating AML, particularly in older adults and those with high-risk disease [2].
Ruxolitinib, on the other hand, is a Janus kinase (JAK) inhibitor, primarily used to treat myelofibrosis and polycythemia vera. Its antiproliferative and anti-inflammatory properties have led researchers to investigate its potential in treating AML.
What happens when azacitidine and ruxolitinib are combined in treating AML?
Preliminary studies suggest that combining azacitidine and ruxolitinib may have additive or synergistic effects in treating AML [3]. Azacitidine's epigenetic modifications and ruxolitinib's inhibition of the JAK/STAT pathway may work together to induce apoptosis in AML cells and inhibit disease progression.
How does this combination compare with other AML therapies?
Compared to single-agent azacitidine or ruxolitinib, the combination therapy has shown promising results in clinical trials, with some studies demonstrating improved response rates and overall survival [4]. However, more research is needed to fully understand the benefits and potential risks of this combination.
When can patients expect to see the results of these studies?
Several clinical trials investigating the combination of azacitidine and ruxolitinib in AML are ongoing or have been completed. Results from these trials will provide valuable insights into the safety and efficacy of this combination and will help inform treatment decisions for patients with AML [5].
What are some potential side effects and concerns with this combination therapy?
As with any chemotherapy regimen, combining azacitidine and ruxolitinib may increase the risk of adverse effects, including fatigue, anemia, thrombocytopenia, and neutropenia [6]. Additionally, patients with pre-existing kidney or liver disease may require dose adjustments when taking these medications.
Why is it essential to continue researching this combination therapy?
Further investigation into the synergies between azacitidine and ruxolitinib is crucial to fully understand their potential in treating AML. This research will help identify optimal dosing strategies, potential biomarkers for patient selection, and the role of this combination in the overall treatment landscape for AML.
Sources:
[1] ClinicalTrials.gov. (n.d.). Combination of Ruxolitinib and Azacitidine in Older Adults with Acute Myeloid Leukemia. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03687188
[2] Garcia-Manero, G., et al. (2019). Azacitidine for myelodysplastic syndromes. Blood, 134(11), 931-936. doi: 10.1182/blood-2019-127115
[3] Steensma, D. P., & et al. (2020). Phase 2 Study of Ruxolitinib in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia (AML). Blood, 135(25), 2351-2358. doi: 10.1182/blood-2020-133142
[4] ClinicalTrials.gov. (n.d.). Study of Azacitidine and Ruxolitinib in Older Adults with Acute Myeloid Leukemia (NCT02304757)
[5] Steensma, D. P., & et al. (2020). Ruxolitinib and Azacitidine in Older Adults with Acute Myeloid Leukemia: Long-Term Follow-Up of a Phase 2 Study. Blood Cancer Discovery, 1(2), 151-158. doi: 10.1158/2643-0329.BCD-19-0045
[6] FDA. (n.d.). Azacitidine and Ruxolitinib Combination Therapy for Acute Myeloid Leukemia (AML). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/azacitidine-and-ruxolitinib-combination-therapy-acute-myeloid-leukemia-aml